Minimal residual disease (MRD) is?a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
This report aims to provide a comprehensive presentation of the global market for Cancer Minimal Residual Disease Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Minimal Residual Disease Testing. This report contains market size and forecasts of Cancer Minimal Residual Disease Testing in global, including the following market information:
- Global Cancer Minimal Residual Disease Testing Market Revenue, 2018-2023, 2024-2029, ($ millions)
- Global Cancer Minimal Residual Disease Testing Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Cancer Minimal Residual Disease Testing companies in 2022 (%)
The global Cancer Minimal Residual Disease Testing market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Flow Cytometry Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Cancer Minimal Residual Disease Testing include Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health and ICON plc, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cancer Minimal Residual Disease Testing manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Minimal Residual Disease Testing Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cancer Minimal Residual Disease Testing Market Segment Percentages, by Type, 2022 (%)
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Other
Global Cancer Minimal Residual Disease Testing Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cancer Minimal Residual Disease Testing Market Segment Percentages, by Application, 2022 (%)
- Hematological Malignancies
- Leukemia
- Lymphoma
- Solid Tumors
- Other
Global Cancer Minimal Residual Disease Testing Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cancer Minimal Residual Disease Testing Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Cancer Minimal Residual Disease Testing revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies Cancer Minimal Residual Disease Testing revenues share in global market, 2022 (%)
- Key companies Cancer Minimal Residual Disease Testing sales in global market, 2018-2023 (Estimated), (K Units)
- Key companies Cancer Minimal Residual Disease Testing sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Adaptive Biotechnologies Corporation
- ArcherDX, Inc. (Invitae Corporation)
- Asuragen
- Arup Laboratories
- Bio-Rad Laboratories
- Cergentis B.V.
- F. Hoffmann- La Roche Ltd
- Guardant Health
- ICON plc
- Invivoscribe
- Laboratory Corporation of America Holdings
- Mission Bio
- Natera, Inc.
- NeoGenomics Laboratories
- Opko Health
- Quest Diagnostics Incorporated
- Sysmex Corporation
- Genetron Health
Outline of Major Chapters:
- Chapter 1: Introduces the definition of Cancer Minimal Residual Disease Testing, market overview.
- Chapter 2: Global Cancer Minimal Residual Disease Testing market size in revenue and volume.
- Chapter 3: Detailed analysis of Cancer Minimal Residual Disease Testing manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of Cancer Minimal Residual Disease Testing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
- Chapter 8: Global Cancer Minimal Residual Disease Testing capacity by region & country.
- Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
- Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
- Chapter 11: The main points and conclusions of the report.
